Clinical Trials Logo

Migraine clinical trials

View clinical trials related to Migraine.

Filter by:

NCT ID: NCT00283738 Active, not recruiting - Migraine Clinical Trials

MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant

Start date: February 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of the study is to investigate the safety and effectiveness of PFO closure with the BioSTAR Septal Repair Implant System in a population of patients that have refractory migraine (with aura) and who have failed medications.

NCT ID: NCT00272896 Completed - Migraine Clinical Trials

Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide in Migraineurs

Start date: October 2004
Phase: N/A
Study type: Interventional

We hypothesized that infusion of VIP may induce headache/migraine in migraineurs and that VIP-induced headache may be associated with dilation of intra- and extracranial vessels. To test this hypothesis, we performed a double blind placebo-controlled crossover study in migraineurs and studied the effect on headache and cerebral and systemic hemodynamic parameters.

NCT ID: NCT00259649 Completed - Migraine Clinical Trials

Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

Start date: August 2004
Phase: Phase 4
Study type: Interventional

Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

NCT ID: NCT00259636 Withdrawn - Fibromyalgia Clinical Trials

Zonisamide for Fibromyalgia & Migraine

Start date: August 2004
Phase: Phase 4
Study type: Interventional

Patients with fibromyalgia & migraine are randomized to receive zonisamide or placebo.

NCT ID: NCT00257010 Completed - Migraine Clinical Trials

A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of almotriptan malate (a migraine headache medication) in the treatment of migraine headaches in adolescents for up to one year.

NCT ID: NCT00256802 Completed - Healthy Volunteers Clinical Trials

The Diameter of the Middle Cerebral Artery Measured With Magnetic Resonance Angiography

Start date: June 2004
Phase: N/A
Study type: Interventional

To examine the ability of MRA to measure the effect of GTN on the intra-cranial vascular response during the GTN-induced headache in healthy volunteers.

NCT ID: NCT00253175 Completed - Migraine Clinical Trials

A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine

Start date: October 2000
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the effectiveness and safety of topiramate (an epilepsy medication) compared with placebo in the prevention of migraine.

NCT ID: NCT00250458 Completed - Migraine Clinical Trials

Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea

Start date: March 2006
Phase: Phase 3
Study type: Interventional

Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.

NCT ID: NCT00246337 Completed - Migraine Clinical Trials

A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.

NCT ID: NCT00240630 Completed - Migraine Clinical Trials

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.